Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1

Cancer Letters

Volumn 265, Issue 2, 2008, Pages 298-306

  Zhang, Yuexing ^a,b   Akinmade, Damilola ^a,b   Hamburger, Anne W ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Breast cancer; EBP1; ErbB2; Heregulin

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NEU DIFFERENTIATION FACTOR; PROTEIN EBP1; PROTEIN KINASE B; RNA BINDING PROTEIN; SHORT HAIRPIN RNA;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; NEUREGULIN-1; RECEPTOR, ERBB-3; RNA-BINDING PROTEINS; TRANSFECTION;

EID: 44149094557     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.024     Document Type: Article

References (33)

1. Holbro T., Civenni G., and Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 284 (2003) 99-110
2. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
3. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., and Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
4. Lemoine N.R., Barnes D.M., Hollywood D.P., Hughes C.M., Smith P., Dublin E., Prigent S.A., Gullick W.J., and Hurst H.C. Expression of the ERBB3 gene product in breast cancer. Br. J. Cancer 66 (1992) 1116-1121
5. Wiseman S.M., Makretsov N., Nielsen T.O., Gilks B., Yorida E., Cheang M., Turbin D., Gelmon K., and Huntsman D.G. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103 (2005) 1770-1777
6. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B.J., Sela M., and Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15 (1996) 2452-2467
7. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas III C.F., and Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100 (2003) 8933-8938
8. Kraus M.H., Issing W., Miki T., Popescu N.C., and Aaronson S.A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA 86 (1989) 9193-9197
9. Plowman G.D., Whitney G.S., Neubauer M.G., Green J.M., McDonald V.L., Todaro G.J., and Shoyab M. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl. Acad. Sci. USA 87 (1990) 4905-4909
10. Pinkas-Kramarski R., Shelly M., Glathe S., Ratzkin B.J., and Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J. Biol. Chem. 271 (1996) 19029-19032
11. Diamonti A.J., Guy P.M., Ivanof C., Wong K., Sweeney C., and Carraway III K.L. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc. Natl. Acad. Sci. USA 99 (2002) 2866-2871
12. Qiu X.B., and Goldberg A.L. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc. Natl. Acad. Sci. USA 99 (2002) 14843-14848
13. Yoo J.Y., Wang X.W., Rishi A.K., Lessor T., Xia X.M., Gustafson T.A., and Hamburger A.W. Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br. J. Cancer 82 (2000) 683-690
14. Lessor T.J., Yoo J.Y., Xia X., Woodford N., and Hamburger A.W. Ectopic expression of the ErbB-3 binding protein EBP1 inhibits growth and induces differentiation of human breast cancer cell lines. J. Cell. Physiol. 183 (2000) 321-329
15. Xia X., Cheng A., Lessor T., Zhang Y., and Hamburger A.W. EBP1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J. Cell. Physiol. 187 (2001) 209-217
16. Zhang Y.X., Woodford N., Xia X.M., and Hamburger A.W. Repression of E2F1-mediated transcription by the ErbB3 binding protein EBP1 involves histone deacetylases. Nucleic Acids Res. 31 (2003) 2168-2177
17. Zhang Y., and Hamburger A.W. Heregulin regulates the ability of the ErbB3-binding protein EBP1 to bind E2F promoter elements and repress E2F-mediated transcription. J. Biol. Chem. 279 (2004) 26126-26133
18. Zhang Y., Akinmade D., and Hamburger A.W. The ErbB3 binding protein EBP1 interacts with Sin3A to repress E2F1 and AR-mediated transcription. Nucleic Acids Res. 33 (2005) 6024-6033
19. Bose S.K., Sengupta T.K., Bandyopadhyay S., and Spicer E.K. Identification of EBP1 as a component of cytoplasmic bcl-2 mRNP (messenger ribonucleoprotein particle) complexes. Biochem. J. 396 (2006) 99-107
20. Squatrito M., Mancino M., Donzelli M., Areces L.B., and Draetta G.F. EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene 23 (2004) 4454-4465
21. Squatrito M., Mancino M., Sala L., and Draetta G.F. EBP1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2alpha phosphorylation. Biochem. Biophys. Res. Commun. 344 (2006) 859-868
22. Chen R., Kim O., Yang J., Sato K., Eisenmann K.M., McCarthy J., Chen H., and Qiu Y. Regulation of Akt/PKB activation by tyrosine phosphorylation. J. Biol. Chem. 276 (2001) 31858-31862
23. Zhang Y., and Hamburger A.W. Specificity and heregulin regulation of EBP1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling. Br. J. Cancer 92 (2005) 140-146
24. Zhang Y.X., Fondell J.D., Wang Q.B., Xia X.M., Cheng A.W., Lu M.L., and Hamburger A.W. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, EBP1. Oncogene 21 (2002) 5609-5618
25. Aguilar Z., Akita R.W., Finn R.S., Ramos B.L., Pegram M.D., Kabbinavar F.F., Pietras R.J., Pisacane P., Sliwkowski M.X., and Slamon D.J. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18 (1999) 6050-6062
26. Bacus S.S., Gudkov A.V., Zelnick C.R., Chin D., Stern R., Stancovski I., Peles E., Ben-Baruch N., Farbstein H., and Lupu R. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res. 53 (1993) 5251-5261
27. van der B.B., Rutteman G.R., Blankenstein M.A., de Laat S.W., and van Zoelen E.J. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J. Cell. Physiol. 134 (1988) 101-108
28. Neve R.M., Holbro T., and Hynes N.E. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 21 (2002) 4567-4576
29. Jhabvala-Romero F., Evans A., Guo S., Denton M., and Clinton G.M. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 22 (2003) 8178-8186
30. Yen L., Cao Z., Wu X., Ingalla E.R., Baron C., Young L.J., Gregg J.P., Cardiff R.D., Borowsky A.D., Sweeney C., and Carraway III K.L. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res. 66 (2006) 11279-11286
31. Peles E., Lamprecht R., Ben-Levy R., Tzahar E., and Yarden Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3′-kinase and its release by oncogenic activation. J. Biol. Chem. 267 (1992) 12266-12274
32. Hui R., Finney G.L., Carroll J.S., Lee C.S., Musgrove E.A., and Sutherland R.L. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res. 62 (2002) 6916-6923
33. McIntosh G.G., Anderson J.J., Milton I., Steward M., Parr A.H., Thomas M.D., Henry J.A., Angus B., Lennard T.W., and Horne C.H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11 (1995) 885-891